XML 54 R37.htm IDEA: XBRL DOCUMENT v3.20.2

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Impairment of intangible assets			$ 584,509	$ 78,864
Amortization of intellectual property license fee	$ 762,389	$ 15,998	2,262,002	15,998
Inventory valuation reserves	5,744,464		$ 5,744,464		$ 0
Council License Agreement [Member]
Property, Plant and Equipment [Line Items]
Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent			50.00%
Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent			20.00%
Maximum costs and expenses for post approval			$ 20,000,000
Council License Agreement Step 1
Property, Plant and Equipment [Line Items]
Royalty (percent)			5.00%
Council License Agreement Step 2
Property, Plant and Equipment [Line Items]
Royalty (percent)			10.00%
Council License Agreement Step 3
Property, Plant and Equipment [Line Items]
Royalty (percent)			15.00%
Vitamins and IMVEXXY [Member]
Property, Plant and Equipment [Line Items]
Shelf life of prescription products following product expiration			24 months
BIJUVA and ANNOVERA [Member]
Property, Plant and Equipment [Line Items]
Shelf life of prescription products following product expiration			18 months
BIJUVA and ANNOVERA [Member] | Knight License Agreement [Member]
Property, Plant and Equipment [Line Items]
Milestone payment received upon regulatory approval	$ 2,000,000
ANNOVERA [Member] | Council License Agreement [Member]
Property, Plant and Equipment [Line Items]
Milestone payment upon FDA Approval			$ 20,000,000
Milestone payments (payment after release of first commercial batch)			20,000,000
License rights acquired			20,000,000
Milestone payments upon specified levels of cumulative net sales			40,000,000
Specified level one of cumulative net sales for milestone payments			200,000,000
Specified level two of cumulative net sales for milestone payments			400,000,000
Specified level three of cumulative net sales for milestone payments			$ 1,000,000,000
Minimum [Member]
Property, Plant and Equipment [Line Items]
Return period of unsalable prescription products			6 months
Minimum [Member] | Council License Agreement Step 2
Property, Plant and Equipment [Line Items]
Net sales amount per step-based royalty			$ 50,000,000
Minimum [Member] | Council License Agreement Step 3
Property, Plant and Equipment [Line Items]
Net sales amount per step-based royalty			$ 150,000,000
Maximum [Member]
Property, Plant and Equipment [Line Items]
Return period of unsalable prescription products			12 months
Maximum [Member] | Council License Agreement Step 1
Property, Plant and Equipment [Line Items]
Net sales amount per step-based royalty			$ 50,000,000
Maximum [Member] | Council License Agreement Step 2
Property, Plant and Equipment [Line Items]
Net sales amount per step-based royalty			$ 150,000,000
Performance Shares [Member]
Property, Plant and Equipment [Line Items]
Common stock, shares, issued (in dollars per share)	$ 0.001		$ 0.001
Restricted Stock [Member]
Property, Plant and Equipment [Line Items]
Common stock, shares, issued (in dollars per share)	$ 0.001		$ 0.001
Trademarks and Trade Names [Member]
Property, Plant and Equipment [Line Items]
Impairment of intangible assets			$ 584,509	78,864
Fair Value, Recurring [Member]
Property, Plant and Equipment [Line Items]
Assets or liabilities valued at fair value	$ 0	$ 0	$ 0	$ 0

X

- Definition

The amount represents amortization of intellectual property license fee.

+ References

No definition available.

+ Details

Name:	txmd_AmortizationOfIntellectualPropertyLicenseFee
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The percentage of annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent.

+ References

No definition available.

+ Details

Name:	txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix:	txmd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.

+ References

No definition available.

+ Details

Name:	txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix:	txmd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.

+ References

No definition available.

+ Details

Name:	txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The amount of milestone payment received upon regulatory approval.

+ References

No definition available.

+ Details

Name:	txmd_MilestonePaymentReceivedUponRegulatoryApproval
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The amount of milestone payments upon FDA approval.

+ References

No definition available.

+ Details

Name:	txmd_MilestonePaymentUponFDAApproval
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of milestone payments payable after release of first commercial batch.

+ References

No definition available.

+ Details

Name:	txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Milestone payments due upon specified levels of cumulative net sales for under agreement.

+ References

No definition available.

+ Details

Name:	txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The net sales amount as defined in license agreement for step-based royalty payments.

+ References

No definition available.

+ Details

Name:	txmd_NetSalesAmountPerStepbasedRoyalty
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Period the company accepts returns of unsalable prescription products from customers following product expiration.

+ References

No definition available.

+ Details

Name:	txmd_ReturnPeriodOfUnsalablePrescriptionProducts
Namespace Prefix:	txmd_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The percent of the net sales to be paid as royalty per license agreement.

+ References

No definition available.

+ Details

Name:	txmd_RoyaltyPercent
Namespace Prefix:	txmd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Period shelf life of prescription products from date of manufacture.

+ References

No definition available.

+ Details

Name:	txmd_ShelfLifeOfPrescriptionProducts
Namespace Prefix:	txmd_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount represents specified level one of cumulative net sales for milestone payments.

+ References

No definition available.

+ Details

Name:	txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The amount represents specified level three of cumulative net sales for milestone payments.

+ References

No definition available.

+ Details

Name:	txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The amount represents specified level two of cumulative net sales for milestone payments.

+ References

No definition available.

+ Details

Name:	txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments
Namespace Prefix:	txmd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Fair value of asset after deduction of liability.

+ References

No definition available.

+ Details

Name:	us-gaap_FairValueNetAssetLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

+ Details

Name:	us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of valuation reserve for inventory.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_InventoryValuationReserves
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_PropertyPlantAndEquipmentLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Per share or per unit amount of equity securities issued.

+ References

No definition available.

+ Details

Name:	us-gaap_SharesIssuedPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=txmd_VitaminsAndImvexxyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=txmd_KnightLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=txmd_AnnoveraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: